Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy
暂无分享,去创建一个
T. Peng | Xiwen Liao | Hao Su | Xinping Ye | Z. Lv | Zhi-ming Zeng | Chuangye Han | Hua-sheng Huang | Xiao Shen | Guangzhi Zhu | Yongguang Wei | Y. Jia | Xiao-Qiang Shen
[1] G. Cabibbo,et al. COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma. , 2022, The Lancet. Oncology.
[2] M. Kudo. Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma , 2022, Liver Cancer.
[3] W. Lau,et al. A novel Peng's test in reducing bile leakage after partial hepatectomy for hepatocellular carcinoma: From an animal study to a clinical cohort Propensity score matching comparative study. , 2022, International journal of surgery.
[4] Lalu Muhammad Irham,et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The lancet. Gastroenterology & hepatology.
[5] Liyong Pu,et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial , 2022, Journal for ImmunoTherapy of Cancer.
[6] K. Hasegawa,et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors , 2022, Journal of hepato-biliary-pancreatic sciences.
[7] V. Mazzaferro,et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification , 2022, Gut.
[8] Xiao-Li Zhu,et al. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response , 2022, Frontiers in Immunology.
[9] R. Zheng,et al. Cancer incidence and mortality in China, 2016 , 2022, Journal of the National Cancer Center.
[10] Xiao-Li Zhu,et al. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma , 2022, Frontiers in Oncology.
[11] Yongheng Chen,et al. Recent advances in systemic therapy for hepatocellular carcinoma , 2022, Biomarker research.
[12] V. Cristini,et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.
[13] L. Rimassa,et al. Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma. , 2022, The lancet. Gastroenterology & hepatology.
[14] Meredith R. Legg,et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. , 2022, The lancet. Gastroenterology & hepatology.
[15] Haitao Zhao,et al. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma , 2021, World journal of gastroenterology.
[16] N. Lyu,et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Salem. Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] V. Mazzaferro,et al. Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.
[19] Li Xu,et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Helmink,et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.
[21] Ludmila V. Danilova,et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity , 2021, Nature Cancer.
[22] S. Jain,et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. , 2021, The Lancet. Oncology.
[23] Y. Ling,et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial. , 2021 .
[24] Minshan Chen,et al. Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma , 2021, Journal of hepatocellular carcinoma.
[25] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[26] A. Cervantes,et al. Hepatocellular carcinoma , 2021, Nature Reviews Disease Primers.
[27] T. Peng,et al. Molecular mechanism of CK19 involved in the regulation of postoperative recurrence of HBV-associated primary hepatocellular carcinoma in Guangxi , 2021, Annals of translational medicine.
[28] Jianming Xu,et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.
[29] K. Lan,et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma , 2020, Journal for ImmunoTherapy of Cancer.
[30] M. Kudo,et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Bruix,et al. Local and Regional Therapies for Hepatocellular Carcinoma , 2020, Hepatology.
[32] Zhao-You Tang,et al. Targeting angiogenesis for liver cancer: Past, present, and future , 2020, Genes & diseases.
[33] Y. Imai,et al. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial , 2019, Liver Cancer.
[34] Shanshan Liu,et al. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma , 2019, Journal of Experimental & Clinical Cancer Research.
[35] P. Sharma,et al. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma , 2019, Cancer Immunology Research.
[36] M. He,et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] B. Choi,et al. Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation. , 2019, Journal of vascular and interventional radiology : JVIR.
[38] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[39] K. Dono,et al. The Branching Pattern of the Inferior Pancreaticoduodenal Artery in Patients with a Replaced Right Hepatic Artery , 2018, The American surgeon.
[40] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[41] Kichang Han,et al. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study , 2018, CardioVascular and Interventional Radiology.
[42] S. Ikeda,et al. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies , 2017, Molecular Cancer.
[43] Ashutosh Kumar Singh,et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.
[44] R. Lencioni,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data , 2016, Hepatology.
[45] P. Hegde,et al. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.
[46] W. Lau,et al. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus , 2016, Medicine.
[47] K. Dandekar,et al. Right Hepatic Artery: A Cadaver Investigation and Its Clinical Significance , 2015, Anatomy research international.
[48] S. Ye,et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study , 2015, Medical Oncology.
[49] Hong Wu,et al. Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. , 2014, The Journal of surgical research.
[50] Lequn Li,et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma , 2014, Annals of surgery.
[51] K. Soo,et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.
[52] T. Nishimura,et al. Redistribution of multiple hepatic arteries into a single hepatic artery to perform repeated hepatic arterial infusion chemotherapy , 2008, Acta radiologica.
[53] S. Kawasaki,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.
[54] R. Dhanasekaran,et al. Implications of genetic heterogeneity in hepatocellular cancer. , 2022, Advances in cancer research.
[55] P. Fisher,et al. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. , 2021, Advances in cancer research.
[56] R. Jain,et al. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. , 2019, Hepatology.